EU SGLT2 Inhibitor Market 2023 Share, Size, Key Players, Revenue Analysis | Prudent Markets

The EU SGLT2 Inhibitor Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global EU SGLT2 Inhibitor market. This report explores all the key factors affecting the growth of the global EU SGLT2 Inhibitor market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141759/

Report Description of the EU SGLT2 Inhibitor Market Analysis

Research Scope and Assumption

The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)

The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis

We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses

All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis

Inflation has not been accounted for in order to estimate and forecast the market

Numbers may not add up due to rounding off

Reason to buy the report:

Facilitate decision-making based on strong current and forecast data for EU SGLT2 Inhibitor Market Analysis

Develop strategies based on the latest regulatory framework

Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market

Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the EU SGLT2 Inhibitor Market Analysis

Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders

To strategically profile key players and comprehensively analyze their market shares and core competencies

We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

EU SGLT2 Inhibitor Market Analysis Executive Summary

SGLT2 inhibition effectively lowers blood glucose levels and also accords other benefits, such as weight loss, low incidence of hypoglycaemia, and reduction in blood pressure. SGLT2 inhibitor is the newest addition into the armamentarium to treat Type-2 Diabetes. Kidney plays a very important role in glucose homeostasis by regulating gluconeogenesis, glucose uptake from the circulation, and glucose reabsorption from the urine filtered in the renal glomeruli.

Market Size and Key Findings

The EU SGLT2 Inhibitor Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 17% during the forecast period.

The size of the SGLT2 Inhibitor Market in the Europe is predicted to be growing at a CAGR of 17% from 2021 to 2028.

Market Dynamics

Market Growth Drivers Analysis

The exponential growth of diabetic population YoY, especially type 2 diabetic patients, new innovative drugs are coming up in the market to increase the ease of access to the patients. With the increase in diabetic population, the need and demand for diabetes drugs are expected to increase. The other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.

Market Restraints

The older patient group and clinical inertia are the main barriers to initiate SGLT2i for eligible patients. Clinicians should change the glucocentric approach and focus on reducing renal events in T2D.

Competitive Landscape

Company Coverage: -
Eli Lilly
Janssen Pharmaceuticals
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Products in Pipeline

A handful of SGLT2 inhibitors have been approved for the treatment of type 2 diabetes or are currently undergoing clinical trials. Currently there are three SGLT2 selective inhibitors approved by the Food and Drug Administration (FDA) for mono, dual, and triple therapy: canagliflozin (Invokana), dapagliflozin (Farxiga) and empagliflozin (Jardiance)

Notable Recent Deals

EU approval should give AZ and BMS first-to-market advantage over other companies developing SGLT2 inhibitors, notably Johnson & Johnson's canagliflozin and Boehringer Ingelheim/Eli Lilly's empagliflozin. Canagliflozin was filed for approval in the US in June, while empagliflozin is scheduled for regulatory submissions during 2013.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

On 25 February 2016, the European Medicines Agency (EMA) confirmed recommendations1 to minimise the risk of diabetic in patients taking SGLT2 inhibitors (a class of type 2 diabetes medicines).

Diabetic is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening ones, have occurred in patients taking SGLT2 inhibitors for type 2 diabetes and a number of these cases have been atypical, with patients not having blood sugar levels as high as expected.

An atypical presentation of diabetic can delay diagnosis and treatment. Healthcare professionals should therefore consider the possibility in patients taking SGLT2 inhibitors who have symptoms consistent with the condition even if blood sugar levels are not high.

Following a review of the cases, EMA recommended updating the product information of SGLT2 inhibitors to list diabetic as a rare adverse reaction (affecting up to 1 in 1,000 patients).

Patients taking these medicines should be aware of the symptoms of diabetic, including rapid weight loss, nausea or vomiting, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat. Patients should contact a doctor or the nearest hospital straightaway if they have any of these symptoms.

If diabetic is suspected or confirmed, treatment with SGLT2 inhibitors should be stopped immediately and should not be re-started unless another cause for the is identified and resolved.

Healthcare professionals should exercise caution with SGLT2 inhibitors in patients with risk factors for and inform patients of these factors. These include low insulin-producing capacity in the pancreas, a sudden drop in a patient's insulin dose, increased insulin requirement (due to illness, surgery or alcohol abuse) or conditions that can restrict food intake or lead to severe dehydration.
To Know More About COVID-19 Impact On EU SGLT2 Inhibitor Market @ https://www.prudentmarkets.com/sample-request/141759/

EU SGLT2 Inhibitor Market Analysis Segmentation

By Drug Class:

Jardiance has the highest growth among all the drugs in the SGLT2 class, in terms of revenue, with an expected CAGR of about 22.51%, during the forecast period. Jardiance was reported to have less cardiovascular risk among other oral drugs. Jardiance is a once-daily oral medication that is used to control blood glucose levels in people with type 2 diabetes.

By Country:

The Europe Sodium-dependent Glucose Cotransporter 2 (SGLT - 2) Market report quantifies the market share held by the significant players of the industry and gives an in-depth view of the competitive landscape. This market is classified into different segments with a comprehensive analysis of each with respect to a geography for the research period.

Highlighted Segments of EU SGLT2 Inhibitor Market:

Industry Overview: The first section of the research study covers an overview of the global EU SGLT2 Inhibitor Market, market status and prospects, and product range. In addition, it provides highlights of the major segments of the global Market, i.e., region, type, and application segments.

Competitive Analysis: This report illuminates important mergers and acquisitions, business expansion, product or service differences, market concentration, the competitive status of the global EU SGLT2 Inhibitor Market, and market size by player.

Company Profiles and Key Data: This section covers companies profiling the major players in the global EU SGLT2 Inhibitor Market based on the aforementioned revenue, products, business, and other factors.

Market size by type and application: In addition to providing an in-depth analysis of the industry size by type and application, this section provides research on top end users or consumers and potential applications.

Market Dynamics: This report covers the drivers, trends, and opportunities of the global EU SGLT2 Inhibitor Market. This section also includes Porter's analysis of five forces.

Findings and Conclusions: It provides strong recommendations for new as well as established players for securing a position of strength in the global EU SGLT2 Inhibitor Market.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141759/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global EU SGLT2 Inhibitor Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global EU SGLT2 Inhibitor Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the EU SGLT2 Inhibitor market
Chapter 2: Exclusive Summary - the basic information of the EU SGLT2 Inhibitor Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the EU SGLT2 Inhibitor
Chapter 4: Presenting the EU SGLT2 Inhibitor Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the EU SGLT2 Inhibitor market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Why should you purchase this report?

-Prudent Markets provides the vital historical and analysis data of global EU SGLT2 Inhibitor market.
-The report provides the entire assessment of the future market and altering market scenario or behavior.
-All the business decision could be backed through the several strategic business methodologies offered in the report.
-An extra edge in the competitive market could be obtained from this elaborative research report
-The report offers all the competitive landscape, growth drivers, applications, market dynamics, and other necessary details as well.

Purchase this report (Single User License) @ https://www.prudentmarkets.com/checkout/?id=141759&license_type=su

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the EU SGLT2 Inhibitor Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.